 Greenberg Traurig Maher Articles Greenberg Traurig Maher (GTM) and Willkie Farr & Gallagher have taken roles on AstraZeneca's $1.15bn (£740m) acquisition of US pharma company Pearl Therapeutics.
AstraZeneca - the UK's second-largest drugs company - will acquire 100% of Pearl's shares for $560m (£361m) cash, with further funds of $450m (£290m) and $140m (£90m) payable if certain regulatory and sales-related milestones are reached. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
